Company Overview and News
Apparel retailer American Eagle Outfitters (AEO) is scheduled to report its fiscal first-quarter earnings on May 31. Wall Street expects the company’s revenue to grow 5.7% to $805.2 million, marking a significant improvement over the 1.7% growth seen in the prior-year quarter.
Ahead of American Eagle Outfitters’ (AEO) upcoming fiscal first-quarter results on May 31, most (53.0%) of the 19 analysts covering the stock recommend “hold,” 42.0% recommend “buy,” and 5.0% recommend “sell.” In the quarter, analysts expect American Eagle Outfitters’ top and bottom lines to grow 5.7% and 37.5%, respectively.
As of May 21, American Eagle Outfitters (AEO) stock had risen 21.1% year-to-date. In comparison, Abercrombie & Fitch (ANF) and Urban Outfitters (URBN) had rise 50.4% and 20.6%, respectively, while Gap (GPS) had fallen 6.9%. The S&P 500 had risen 2.2%.
Analysts expect American Eagle Outfitters’ (AEO) EPS (earnings per share) to grow 37.5% to $0.22 in the fiscal first quarter, marking a significant improvement over the 27% decline witnessed in the prior-year quarter. Improved revenue and profits are expected to cushion its bottom line.
GameStop Corp. (GME - Free Report) is expected to report first-quarter fiscal 2018 results on May 24. In the trailing four quarters, this consumer electronics’ retailer has outperformed the Zacks Consensus Estimate by an average of 12.7%. In the last reported quarter, the company delivered a positive earnings surprise of 3.1%. Let’s delve deep and take a look at the factors that will be influencing the quarterly results.
Hibbett Sports, Inc. (HIBB - Free Report) is slated to release first-quarter fiscal 2019 results on May 25, before the market opens. The company boasts an impressive earnings surprise history with a beat in each of the last four quarters by an average of 26.1%. Notably, the Zacks Consensus Estimate for the first quarter is pegged at $1.13, which has been stable in the last 30 days but reflects a year-over-year increase of 16.
The majority of the analysts covering Urban Outfitters (URBN) stock have maintained a “hold” rating ahead of its upcoming fiscal Q1 2019 results, which the company plans to release on May 22. As of May 16, of the 22 analysts covering the stock, 55% recommended a “hold,” 41% recommended a “buy,” and 4% recommended a “sell.”
Urban Outfitters (URBN) plans to report first-quarter fiscal 2019 results on May 22. Analysts expect the company to report sales of $837.4 million, representing growth of 10.0% on a YoY (year-over-year) basis.
Analysts expect Urban Outfitters’ adjusted EPS to be $0.30 in the first quarter of fiscal 2019, more than double the EPS in the corresponding quarter last year. Further, analysts expect the company to report a gross margin of 32.6%, up 110 basis points on a YoY basis in the first quarter of fiscal 2019. The company’s adjusted SG&A (selling, general, and administrative) expenses are projected to be up 3.
Soros' 13F portfolio value increased from $4.37B to $6.16B this quarter. The number of positions increased from 196 to 219.
The Gap, Inc. (GPS - Free Report) is slated to report first-quarter fiscal 2018 results on May 24. The company has delivered a positive earnings surprise in each of the trailing four quarters, with an average of 11.1%. The Zacks Consensus Estimate for first-quarter earnings is pegged at 45 cents, mirroring a year-over-year improvement of 25%. However, the estimate has moved down by a penny in the last seven days.
Deere & Company (DE - Free Report) is scheduled to report second-quarter fiscal 2018 results on May 18, before the market opens. In the last reported quarter, Deere posted earnings of $1.31 per share, beating the Zacks Consensus Estimate by around 13%. Moreover, the company’s earnings surpassed estimates in each of the trailing four quarters, recording an average positive earnings surprise of 17.25%.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
The Bath & Body Works segment within L Brands is overlooked due to its revenue base being much lower than the Victoria's Secret segment.
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
as of ET